Lilly places $1b bet on AlzeCure’s Alzheimer’s project (opens in new tab)

A small Swedish biotech lands a potentially billion-dollar deal as the race shifts from treating Alzheimer’s to preventing it. Promising Alzheimer’s therapies have stumbled in clinical trials, billions of dollars have been spent chasing elusive biological targets and, despite recent progress, researchers are still wrestling with difficult realities. By the time symptoms appear, Alzheimer’s disease […] The post appeared first on <a href="